Shares of Nektar Therapeutics (NKTR) more than doubled on Tuesday afternoon after the company announced that its mid-stage study evaluating Rezpegaldesleukin in atopic dermatitis demonstrated ...

Nektar's (NKTR) shares rally almost 75% in a week on corrected efficacy data for rezpeg studies, earlier miscalculated by Eli Lilly.

Nektar Therapeutics (NASDAQ: NKTR) stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a midstage study of its eczema treatment.

The latest biotech stock to explode in price, Nektar Therapeutics (NASDAQ: NKTR) was quite the outperformer on the stock exchange for the second day in a row. On Wednesday, one day after ...

BTIG Research and HC Wainwright updated their price targets on the stock to $100 and $120, respectively. As of June 24, the MarketBeat-tracked consensus price target on Nektar was around $76 ...

Nektar Therapeutics said on Thursday it had stopped all trials involving its key cancer drug following its failure in multiple studies, dragging the drug developer's shares down 23% in after ...

Nektar (NKTR) is reportedly suing former partner Eli Lilly (LLY) for allegedly miscalculating clinical trial data for Nektar's dermatology drug candidate Rezpeg. Read more here.

Nektar Therapeutics on Monday sued Eli Lilly , accusing the U.S. drugmaker of undermining the prospects for a drug the companies were developing together for various autoimmune diseases.

The latest biotech stock to explode in price, Nektar Therapeutics (NASDAQ: NKTR) was quite the outperformer on the stock exchange for the second day in a row. On Wednesday, one day after ...